BeStock  
Stocks › Biotechnology › EPRX

Eupraxia Pharmaceuticals EPRX

US equityMarket cap rank #3682Biotechnology
$5.80 −$0.32 (-5.23%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $5.80 0.00%
Open$6.11
Prev close$6.12
Day range$5.69 – $6.42
Volume361.7K
Market cap$390.16M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$16.16M-134.8% YoY
Net profit-$15.25M-139.4% YoY
Diluted EPS-$0.23-21.1% YoY
Free cash flow-$11.46M-151.0% YoY
Operating cash flow-$11.33M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-7.5MDec '24$-6.8MMar '25$-8.7MJun '25$-6.4MSep '25$-16.7MDec '25$-12.7MMar '26$-14.5MJun '26$-15.2MSep '26

Diluted EPS by quarter

-0.22Dec '24-0.21Mar '25-0.26Jun '25-0.19Sep '25-0.37Dec '25-0.23Mar '26-0.23Jun '26-0.23Sep '26

Free cash flow by quarter

$-6.0MDec '24$-6.2MMar '25$-8.5MJun '25$-4.6MSep '25$-9.9MDec '25$-10.5MMar '26$-13.3MJun '26$-11.5MSep '26

Annual revenue

$0.0FY20$0.0FY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-78.9%
Return on assets-52.1%
Return on invested capital-80.4%
Current ratio12.25
Liabilities / assets10.0%
Cash & investments$126.42M
Total debt$2.91M
Net cash (debt)$123.51M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $16.16M $18.10M $15.96M $38.43M $16.16M
Selling and Admin Expenses $5.34M $5.30M $4.78M $17.10M $8.30M
-General & Admin Expense $5.34M $5.30M $4.78M $17.10M $8.30M
Research & Development $10.82M $12.81M $11.17M $21.33M $7.87M
Operating Profit -$16.16M -$18.10M -$15.96M -$38.43M -$16.16M
Net Non-Operating Interest Income (Expense) $1.22M $1.39M $1.07M $1.41M $666,921.00
Non-Operating Interest Income $1.22M $1.39M $1.07M $1.41M $666,921.00
Other Income (Expense) -$313,763.00 $2.25M $2.24M -$1.57M -$1.21M
Gain on Sale of Security -$312,356.00 $2.25M $2.24M -$1.56M -$1.21M
Special Income (Charges) -$1,407.00 -$2,704.00 $0.00 -$2,562.00 -$1,487.00
-Gain on Sale of Property/Plant/Equipment -$1,407.00 -$2,704.00 $0.00 -$2,562.00 -$1,487.00
Pretax Profit -$15.26M -$14.46M -$12.64M -$38.59M -$16.71M
Tax -$7,170.00 $30,381.00 $13,905.00 $19,091.00 $11,339.00
Net Profit -$15.25M -$14.49M -$12.65M -$38.61M -$16.72M
Profit from Continuing Operations -$15.25M -$14.49M -$12.65M -$38.61M -$16.72M
Minority Interests -$6,189.00 -$6,478.00 -$1,415.00 -$29,509.00 -$10,084.00
Net Income to Parent Company -$15.24M -$14.49M -$12.65M -$38.58M -$16.71M
Net Income to Common Stockholders -$15.24M -$15.08M -$12.65M -$38.58M -$16.71M
Basic EPS -$0.23 -$0.23 -$0.23 -$1.03 -$0.37
Diluted EPS -$0.23 -$0.23 -$0.23 -$1.03 -$0.37
Preferred Stock Dividends – $596,050.00 – – –
Non-Operating Interest Expense – – – $0.00 $0.00

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $134.56M $139.91M $145.35M $86.15M $86.15M
Total Current Assets $129.95M $136.80M $142.13M $85.10M $85.10M
Cash and Cash Equivalents & Short-Term Investments $126.42M $133.66M $138.88M $80.56M $80.56M
-Cash and Cash Equivalents $75.18M $52.43M $58.50M $80.56M $80.56M
-Short Term Investments $51.25M $81.23M $80.38M – –
Receivables $202,171.00 $688,219.00 $663,235.00 $674,226.00 $674,226.00
-Taxes Receivable $202,171.00 $688,219.00 $663,235.00 $674,226.00 $674,226.00
Prepaid Assets $3.33M $2.46M $2.58M $3.86M $3.86M
Total Non-Current Assets $4.61M $3.10M $3.23M $1.05M $1.05M
Net PPE $4.56M $3.05M $3.17M $987,126.00 $987,126.00
-Gross PPE $5.39M $3.81M $3.86M $1.63M $1.63M
-Accumulated Depreciation -$830,243.00 -$756,638.00 -$693,467.00 -$644,167.00 -$644,167.00
Non-Current Prepaid Assets $50,594.00 $53,702.00 $61,754.00 $64,332.00 $64,332.00
Total Liabilities $13.52M $10.23M $9.17M $5.70M $5.70M
Total Current Liabilities $10.61M $8.55M $7.36M $5.63M $5.63M
Payables $1.16M $1.10M $468,451.00 $1.52M $1.52M
-Total Tax Payable $14,460.00 $21,184.00 $23,390.00 $1,606.00 $1,606.00
-Other Payable $1.14M $1.08M $445,061.00 $1.52M $1.52M
Current Accrued Expenses $8.94M $7.29M $6.69M $4.03M $4.03M
Short-Term Debt and Capital Lease Obligation $511,977.00 $159,877.00 $203,510.00 $78,452.00 $78,452.00
-Current Capital Lease Obligation $511,977.00 $159,877.00 $203,510.00 $78,452.00 $78,452.00
Total Non-Current Liabilities $2.91M $1.68M $1.80M $75,910.00 $75,910.00
Long Term Debt and Capital Lease Obligation $2.91M $1.68M $1.80M $75,910.00 $75,910.00
-Long Term Capital Lease Obligation $2.91M $1.68M $1.80M $75,910.00 $75,910.00
Total Equity $121.05M $129.67M $136.19M $80.45M $80.45M
Stockholders' Equity $121.05M $131.28M $137.78M $82.04M $82.04M
Capital Stock $305.57M $293.70M $285.24M $225.15M $225.15M
-Common Stock $276.05M $264.18M $255.50M $195.41M $195.41M
-Preferred Stock $29.52M $29.52M $29.74M $29.74M $29.74M
Additional Paid-In Capital $34.15M $41.31M $39.27M $28.52M $28.52M
Retained Earnings -$211.96M -$196.72M -$182.23M -$169.58M -$169.58M
Gains/Losses Not Affecting Retained Earnings -$6.71M -$7.01M -$4.48M -$2.04M -$2.04M
Minority Interests $0.00 -$1.60M -$1.60M -$1.60M -$1.60M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$11.33M -$13.09M -$10.15M -$28.55M -$9.73M
Net cash flow from continuing operations -$11.33M -$13.09M -$10.15M -$28.55M -$9.73M
Net Income from Continuing Operations -$15.25M -$14.49M -$12.65M -$38.61M -$16.72M
Gain/Loss from Continuing Operations $288,139.00 -$2.24M -$2.23M $1.57M $1.19M
Depreciation & Depletion & Amortization $183,656.00 $134,935.00 $90,146.00 $237,717.00 $72,806.00
Other Non-Cash Items -$83,095.00 -$907,891.00 -$408,712.00 -$76,945.00 -$18,589.00
Change in Working Capital $1.40M $1.38M $2.80M -$713,700.00 -$231,592.00
-Change in Receivables $501,554.00 -$26,168.00 $23,964.00 -$431,449.00 -$528,267.00
-Change in Prepaid Assets -$874,190.00 $49,457.00 $1.24M -$2.64M -$1.47M
-Change in Payables and Accrued Expense $1.77M $1.35M $1.54M $2.36M $1.76M
Net cash flow from investing $29.94M -$173,092.00 -$80.05M -$588,947.00 -$193,301.00
Net Cash Flow from Continuing Investing Activities $29.94M -$173,092.00 -$80.05M -$588,947.00 -$193,301.00
Net PPE Purchase and Sale -$133,957.00 -$173,092.00 -$326,953.00 -$588,947.00 -$193,301.00
Net Investment Purchase and Sale $30.07M $0.00 -$79.72M – –
Financing Cash Flow $4.18M $7.48M $68.58M $76.06M $1.49M
Net Cash Flow from Continuing Financing Activities $4.18M $7.48M $68.58M $76.06M $1.49M
Net Common Stock Issuance $0.00 -$9.27M $58.63M $73.89M $0.00
Proceeds from Stock Option Exercised $4.18M $16.75M $9.95M $2.17M $1.49M
Ending Cash Balance $75.18M $52.43M $58.50M $80.56M $80.56M
Net Change in Cash $22.79M -$5.79M -$21.62M $46.92M -$8.43M
Beginning Cash Balance $52.43M $58.50M $80.56M $33.10M $88.96M
Effect of Exchange Rate Changes -$42,560.00 -$283,988.00 -$448,176.00 $544,813.00 $33,894.00
Free Cash Flow -$11.46M -$13.27M -$10.47M -$29.14M -$9.92M
Net Issuance Payments Of Debt – – – $0.00 $0.00

Discussion

No comments yet — be the first to weigh in on EPRX.

Sign in to join the discussion.

Scroll to Top